Private GLP-1 Prescriptions UK: Cost Comparison Guide

The private GLP-1 market in the UK has grown substantially, driven by high demand for weight management medications and limited NHS availability. As of 2026, three main GLP-1 receptor agonists are available through private prescriptions:

Wegovy (semaglutide 2.4mg) — Novo Nordisk - Licensed specifically for weight management - Once-weekly subcutaneous injection - Dose escalation from 0.25mg to 2.4mg over 16 weeks - NICE approved for NHS use (with restrictions) - Availability has improved but intermittent shortages continue

Mounjaro (tirzepatide) — Eli Lilly - Licensed for type 2 diabetes; also approved for weight management under the brand name Zepbound in some markets - Once-weekly subcutaneous injection - Dual GIP/GLP-1 receptor agonist (unique mechanism) - Dose escalation from 2.5mg to 15mg - Increasingly available privately in the UK

Saxenda (liraglutide 3mg) — Novo Nordisk - Licensed for weight management - Daily subcutaneous injection - Dose escalation from 0.6mg to 3mg over 4 weeks - Longest-established GLP-1 for weight loss - Generally the most affordable option

Ozempic (semaglutide 1mg) — Novo Nordisk - Licensed for type 2 diabetes only (not weight management) - Prescribed off-label for weight loss by some private clinics - Lower semaglutide dose than Wegovy

Each medication has distinct dosing schedules, efficacy profiles, and cost structures. Understanding these differences is essential for making an informed decision.

Private medication costs in the UK fluctuate based on supply, demand, and provider. The following ranges reflect typical private pharmacy pricing as of early 2026:

Wegovy (semaglutide for weight management): - 0.25mg pen (month 1): £140–180 - 0.5mg pen (month 2): £150–200 - 1mg pen (months 3–4): £180–240 - 1.7mg pen (months 5–8): £200–270 - 2.4mg pen (maintenance): £220–300 - Typical monthly cost at maintenance dose: £220–300

Mounjaro (tirzepatide): - 2.5mg pen (month 1): £150–200 - 5mg pen (month 2): £170–230 - 7.5mg pen (month 3): £190–250 - 10mg pen (month 4): £210–280 - 12.5mg pen (month 5): £230–300 - 15mg pen (maintenance): £250–320 - Typical monthly cost at maintenance dose: £250–320

Saxenda (liraglutide): - Saxenda is sold as multi-dose pens (3ml pens, 6mg/ml) - At maintenance dose (3mg daily), one pen lasts approximately 6 days - Monthly requirement: approximately 5 pens - Typical monthly cost at maintenance dose: £150–220

Ozempic (semaglutide — off-label for weight loss): - 0.25mg/0.5mg pen: £80–150 - 1mg pen: £150–250 - Typical monthly cost: £150–250 (lower dose than Wegovy)

Important note: These prices reflect the medication cost only. Total treatment costs including consultations, blood tests, and monitoring will be higher.

Beyond medication costs, private GLP-1 treatment involves several additional expenses:

Initial consultation fees: - Private GP consultation: £50–150 - Specialist weight management clinic: £100–250 - Online telehealth consultation: £20–80 - Some services include the initial consultation fee in the first month's medication cost

Follow-up consultations: - Monthly check-ins: £20–50 - Quarterly reviews: £40–100 - Many online services bundle follow-ups into a monthly subscription fee - Some clinics charge per consultation; others offer packages

Blood tests: - Initial blood panel (HbA1c, thyroid, renal, liver function): £80–150 - Follow-up blood tests (typically quarterly): £50–100 - Some clinics include blood tests in their service; others require you to arrange them independently - At-home blood test kits are available from £50–80

Total monthly cost estimates (medication + clinical support):

| Treatment | Medication | Clinical Support | Total Monthly | |-----------|-----------|-----------------|---------------| | Saxenda | £150–220 | £30–60 | £180–280 | | Ozempic (off-label) | £150–250 | £30–60 | £180–310 | | Wegovy | £220–300 | £30–60 | £250–360 | | Mounjaro | £250–320 | £30–60 | £280–380 |

Annual cost projection: At these monthly rates, a year of private GLP-1 treatment typically costs £2,200–4,500 depending on the medication and service level chosen. This is a significant financial commitment that should be factored into your decision.

There are several routes to obtaining a private GLP-1 prescription in the UK, each with distinct advantages and limitations:

1. Private GP or specialist clinic (in-person): - Face-to-face consultation with a registered prescriber - Thorough physical examination and medical history review - Blood tests often taken on-site - More comprehensive initial assessment - Higher consultation fees but potentially better clinical oversight - May have established relationships with pharmacies for competitive medication pricing - Best for patients with complex medical histories or multiple comorbidities

2. Online weight management clinics (telehealth): - Video or questionnaire-based consultation - Convenient and accessible from anywhere in the UK - Lower consultation fees - Medication typically delivered to your door - Quality of clinical assessment varies significantly between providers - Some offer comprehensive programmes with dietary coaching; others are prescription-only - Look for services registered with the CQC (Care Quality Commission)

3. Private hospital or specialist obesity clinic: - Most thorough assessment, often including detailed body composition analysis - Access to multidisciplinary teams (endocrinologists, dietitians, psychologists) - Highest consultation fees (£200–500 for initial assessment) - Best clinical governance and monitoring - Suitable for patients with BMI >40 or significant comorbidities

4. Pharmacy prescriber services: - Some pharmacies now employ independent prescribers who can initiate GLP-1 treatment - Convenient for those who prefer face-to-face interaction without a GP appointment - Limited to pharmacies with qualified prescribers - Clinical assessment may be less comprehensive than a GP or specialist consultation

Choosing the right route depends on your medical history, budget, and the level of clinical support you want. For straightforward cases (otherwise healthy individuals with BMI 30–35), online telehealth services may be adequate. For complex cases, in-person specialist assessment is recommended.

Before committing to private treatment, it is worth understanding the NHS pathway and whether it might be suitable for your situation:

NHS GLP-1 eligibility criteria (NICE guidelines): - Wegovy: BMI ≥35 with at least one weight-related comorbidity, or BMI ≥30 for certain populations. Must be prescribed through a specialist weight management service. - Mounjaro: Currently available on the NHS primarily for type 2 diabetes, not weight management. - Saxenda: Available through specialist weight management services for patients meeting similar BMI criteria to Wegovy.

NHS advantages: - No medication cost (standard prescription charge of £9.90 per item, or free in Scotland, Wales, and Northern Ireland) - Integrated into your NHS medical record - Access to multidisciplinary weight management teams - Ongoing monitoring included

NHS limitations: - Long waiting lists for specialist weight management services (often 6–18 months) - Strict eligibility criteria that exclude many people who might benefit - Limited medication choice — prescribers follow NICE recommendations - Periodic supply constraints affecting availability - Treatment duration may be limited by local commissioning decisions

When private treatment makes sense: - You do not meet NHS eligibility criteria but have a clinically appropriate BMI - You cannot wait for NHS referral and assessment timelines - You want access to a specific medication (e.g., Mounjaro for weight management) - You prefer more frequent monitoring and support than the NHS provides - You can comfortably afford the ongoing costs

When NHS is the better option: - You meet NICE eligibility criteria - You have type 2 diabetes (Ozempic and Mounjaro are more readily available on the NHS for diabetes) - Cost is a significant concern - You prefer treatment integrated with your GP and medical records - You have complex comorbidities requiring specialist oversight

Hybrid approach: Some patients start treatment privately to avoid waiting lists and then transition to NHS care once they have established treatment and can demonstrate clinical benefit. Discuss this possibility with both your NHS GP and your private prescriber.

Choosing a private GLP-1 treatment in the UK involves balancing efficacy, cost, convenience, and clinical support. Here are the key considerations:

By efficacy (clinical trial weight loss data): 1. Mounjaro (tirzepatide) — up to 22.5% body weight reduction in trials 2. Wegovy (semaglutide 2.4mg) — approximately 15% body weight reduction 3. Ozempic (semaglutide 1mg) — approximately 10–12% (lower dose) 4. Saxenda (liraglutide) — approximately 8% body weight reduction

By cost (monthly at maintenance): 1. Saxenda — £150–220 (most affordable, but daily injection) 2. Ozempic — £150–250 (off-label, lower dose) 3. Wegovy — £220–300 (licensed for weight management) 4. Mounjaro — £250–320 (highest efficacy, highest cost)

By convenience: 1. Wegovy, Mounjaro, Ozempic — once weekly injection 2. Saxenda — daily injection (less convenient)

Practical recommendations:

1. Do not choose solely on price. The cheapest option is not necessarily the best value. Mounjaro may cost more monthly but delivers greater weight loss, potentially meaning a shorter treatment duration.

2. Factor in the full cost. Include consultations, blood tests, and monitoring in your budget. A "cheap" medication from a service that charges separately for everything may cost more in total than an apparently pricier all-inclusive service.

3. Verify your prescriber. Check GMC registration. Ensure a genuine clinical assessment is conducted. Avoid services that guarantee a prescription before evaluating you.

4. Plan for the long term. GLP-1 treatment is not a short-term fix. Weight regain after discontinuation is well documented. Budget for at least 12 months and have a plan for maintaining results after stopping.

5. Combine with lifestyle changes. GLP-1 agonists are most effective when combined with dietary improvements, regular physical activity, and behavioural support. Medication alone yields suboptimal results.

6. Explore NHS options first. If you qualify, NHS treatment is dramatically cheaper and comes with integrated clinical support.

*This guide is for educational purposes only. Always consult a qualified healthcare professional before starting any medication.*